804 related articles for article (PubMed ID: 19446149)
1. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
[TBL] [Abstract][Full Text] [Related]
2. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
[TBL] [Abstract][Full Text] [Related]
3. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
4. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
5. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
6. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
[TBL] [Abstract][Full Text] [Related]
7. Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Wire MB; Fang L; Hussaini A; Kleha JF; Theodore D
Antimicrob Agents Chemother; 2014 Nov; 58(11):6704-9. PubMed ID: 25155600
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
[TBL] [Abstract][Full Text] [Related]
9. Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.
Krishna G; Kisicki JC; Olsen S; Grasela DM; Wang Z
Pharmacotherapy; 2007 Jul; 27(7):963-9. PubMed ID: 17594201
[TBL] [Abstract][Full Text] [Related]
10. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
11. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
12. Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor.
Shen Z; Lee CA; Valdez S; Yang X; Wilson DM; Flanagan T; Gillen M
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):647-656. PubMed ID: 30748125
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin.
Chandra R; Liu P; Breen JD; Fisher J; Xie C; LaBadie R; Benner RJ; Benincosa LJ; Sharma A
Clin Pharmacokinet; 2007; 46(3):247-59. PubMed ID: 17328583
[TBL] [Abstract][Full Text] [Related]
14. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
Krishna R; East L; Larson P; Valiathan C; Butterfield K; Teng Y; Hernandez-Illas M
J Pharm Pharmacol; 2016 Nov; 68(11):1359-1365. PubMed ID: 27671833
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
Henney HR; Shah J
Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
Wire MB; McLean HB; Pendry C; Theodore D; Park JW; Peng B
Antimicrob Agents Chemother; 2012 Jun; 56(6):2846-51. PubMed ID: 22391553
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
18. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.
Solans A; Carbó ML; Peña J; Nadal T; Izquierdo I; Merlos M
Clin Ther; 2007 May; 29(5):900-908. PubMed ID: 17697908
[TBL] [Abstract][Full Text] [Related]
19. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.
Scott G; Vinluan Reynolds C; Milosavljev S; Langholff W; Shenouda M; Rordorf C
Clin Pharmacokinet; 2004; 43(5):341-8. PubMed ID: 15080766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
